b'AML MRD Assay by MFCClinical Information Using a comprehensive selection of antibodies and Measurable residual disease, also called minimal residuala standardized panel across all testing points, MRD disease (MRD) refers to persistent leukemic cells in the bloodpopulations can be characterized and tracked down to 0.01% or bone marrow of cancer patients during or after treatment.sensitivity. Utilizing up to 12 biomarkers per tube allows for the Undetected or untreated MRD is a main cause identification of more LAIPS with less sample than previously of cancer recurrence hence sensitive MRD tests arewas available before. necessary for guiding optimal treatment programs andThis panel not only provides evaluation and monitoringproviding a prognostic indicator for risk stratification of patients with hematological malignancy but provides of treated patients. a wide array of applications due to its comprehensive Multi-parameter Flow Cytometry (MFC) is a widely acceptedbiomarker selection.platform for assessing MRD in patients with Acute Myeloid Leukemia (AML) and can be performed within a short periodBiomarkers in AML MRD Panelof time. In our lab we utilize a comprehensive panel ofCD2, CD4, CD5, CD7, CD11b, CD13, CD14, CD15, CD16, CD19, antibody markers to characterize potential AML blast cellsCD33, CD34, CD36, CD38, CD45, CD 56, CD64, CD117, CD123, using a LAIP based different from normal (DfN) approach.HLADR, 7AADThis approach takes into account information from diagnosis, if available but also identifies aberrant cells that have differentiated from normal maturation without previous patient history.References1.Schuurhuis, Gerrit J et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood vol. 131,12 (2018): 1275-1291. doi:10.1182/blood-2017-09-801498NCCN 2.Wood BL. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.Curr Protoc Cytom. 2020 Jun;93(1):e73. doi: 10.1002/cpcy.73.PMID: 323118343.Cloos J, Harris JR, Janssen JJWM, Kelder A, Huang F, Sijm G, Vonk M, Snel AN, Scheick JR, Scholten WJ, Carbaat-Ham J, Veldhuizen D, Hanekamp D, Oussoren-Brockhoff YJM, Kaspers GJL, Schuurhuis GJ, Sasser AK, Ossenkoppele G. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. J Vis Exp. 2018 Mar 5;(133):56386. doi: 10.3791/56386.PMID: 29553571 4.Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica. 2019 Aug;104(8):1532-1541. doi: 10.3324/haematol.2018.208454. Epub 2019 Jul 4. PMID: 31273094; PMCID: PMC6669140.5.Zeijlemaker W, Kelder A, Cloos J, Schuurhuis GJ. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.Curr Protoc Cytom. 2019 Dec;91(1):e66. doi: 10.1002/cpcy.66.PMID: 31763792 .6.Dix, C.; Lo, T.-H.; Clark, G.; Abadir, E. Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going. J. Clin. Med. 2020, 9, 171460'